At the end of April, around one billion doses of anti-Covid vaccines had been administered worldwide, or about 13 doses per 100 people. To date, in a big month, the The number of doses injected worldwide has doubled with nearly two billion (1,928,347,028 as of May 31) of doses injected. By the end of March 500 million vaccinations had been administered worldwide. It should be remembered, however, that most vaccines require two doses and that therefore the number of people fully vaccinated is lower than the said figure. But it remains a feat all the same. On this June 1, there are 170,836,935 cases of coronavirus, 3,552,277 dead.
In record time, the planet has “turned” at a rate of injections of more than 30 million per day, whereas only a week ago, we were at about twenty million. However, as the sources are national, he is required to take them with caution. It is in China that the campaign is the most massive, with more than 640 million doses distributed (the country has 1.4 billion inhabitants). The United States nearly 300 million doses follow, then the European Union, which quickly made up for its initial delay with nearly 247 million to date. India’s second most populous country in the world to tackle it late is 216 million in this 1er June, Brazil, the second most deadly country after the United States, stands at 67.7 million, just ahead of the United Kingdom, which is no longer part of the EU with nearly 65 million.
But let’s face it, the progress of the campaigns remains very variable depending on the country and continent. Being born somewhere in Africa or Asia is inevitable compared to having been born or living in Europe or North America, hence this major observation: the lack of cooperation and solidarity with countries poor. But that is not the point. There are now 11 vaccines in use worldwide, including only one single dose, the one recently deployed by, Johnson & Johnson. This vaccine is currently in use in the United States, South Africa, and in some European countries such as Italy and Poland. France, Germany and the Netherlands have also started or will use it. In total, Johnson & Johnson is expected to deliver 55 million doses of vaccine to the European Union by the end of June.
The Oxford-AstraZeneca vaccine is currently the most widely used in the world. With nearly 3 billion doses ordered, the AstraZeneca vaccine has so far been the best-selling vaccine in the world (in North and Latin America, in Western Europe, in North Africa, in South Asia). East and Oceania). At the end of April, 168 countries and territories spread over five continents were administering this vaccine.
Behind AstraZeneca / Oxford (distributed in 168 countries and territories) according to WHO data, the American-German vaccine Pfizer / BioNTech (administered in at least 97 countries), the American Moderna (at least 46), Chinese Sinopharm (at least 45), Russian Sputnik V (at least 40) and American-German Johnson & Johnson (at least 29), Chinese Sinovac and CanSino are administered by, respectively, 30 and 20 countries, mainly in Asia and South America.
Despite its rather chaotic journey – the AstraZeneca vaccine had been temporarily suspended in several countries due to suspected side effects – the vaccine from the Anglo-Swedish biopharmaceutical laboratory AstraZeneca called AZD1222, remains by far the most pre-ordered in the world. The National Medicines Safety Agency had confirmed the existence of a “rare” risk of atypical thrombosis associated with this vaccine, while stressing that its benefit / risk balance remained favorable. The vaccine was originally developed at the Jenner Institute at the University of Oxford.
In April 2020, the two sides announced a partnership that saw AstraZeneca take responsibility for testing, production, marketing and logistics. The company said the vaccine will be sold at cost. The vaccine does not require ultra-cold storage, which sets it apart from some of the other vaccines available. Therefore, AZD1222 has become particularly attractive to countries without an existing ultra-cold supply chain, as well as to developing countries.
AstraZeneca’s Covid-19 vaccine is 76% effective against symptomatic cases, the Swedish-British laboratory announced at the end of March, which revised its protection rate. After an update of its data from a clinical trial in the United States, Peru, and Chile, the results of “Primary analysis of phase III trials (of the vaccine) in the United States confirmed that (its) efficacy was consistent” with the data announced, AstraZeneca had said in a statement, announcing on occasion that the effectiveness of its vaccine was 100% to prevent severe cases of Covid-19.